Indeed, patients with significant liver fibrosis and without NAFLD had a lower CD4 cell count and a higher proportion of exposure to didanosine, while metabolic comorbidities and high BMI were less frequent. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatotic liver disease.